Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 143.18m |
Free float | 132.93m |
P/E (TTM) | -- |
Market cap | 1.26bn USD |
EPS (TTM) | -0.1582 USD |
Data delayed at least 20 minutes, as of Nov 09 2021.
More ▼
Press releases
- Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
- Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
- Aurinia to Participate in Jefferies London Healthcare Conference
- Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
- Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
- Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
- Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
- Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
- Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
- Aurinia Announces Board Restructuring
More ▼